The National Institute of Health (NIH) under the Korea Disease Control and Prevention Agency (KDCA) has developed induced pluripotent stem cells (iPSCs) ready for immediate clinical use and is launching their distribution. The move is seen as laying the groundwork to accelerate therapeutics development by freeing researchers from the costly and complex process of producing "source cells" on their own.
The NIH announced on the 29th that it will begin distributing clinical-grade iPSC lines to domestic research institutions and bio companies. iPSCs are cells created by reprogramming ordinary cells, such as skin cells, back to an "initial state," which can then be re-differentiated into various cell types. They hold significant value as they can be used to develop blood components such as red blood cells and platelets, as well as a wide range of cell-based therapeutics. Notably, "clinical-grade" cells produced under Good Manufacturing Practice (GMP) standards for pharmaceutical production have secured the quality and safety levels required for actual patient treatment research.
The achievement is a result of the "Cell-Based Artificial Blood Manufacturing and Demonstration Platform" project jointly pursued by related government ministries including the Ministry of Health and Welfare. Artificial blood technology, which uses stem cells to produce red blood cells or platelets, is considered a key alternative to solving the shortage of blood for transfusions. It is also regarded as a foundational technology applicable to the development of various cell-based therapeutics.
The cells established this time were primarily made from Type O blood, which causes fewer rejection reactions during transfusions. The institute secured a total of 18 cell lines, and among them, one has been developed into a Master Cell Bank (MCB). An MCB is a standardized raw material repository designed to supply large quantities of cells with consistent quality in a stable manner, serving as core infrastructure that can be directly utilized in clinical research. This marks the first time a clinical-grade iPSC-based MCB has been established in South Korea.
Previously, researchers had to go through the high-cost, highly complex cell production process themselves to develop cell-based therapeutics. However, with the government now providing standardized cells, the time and costs involved in the early research stage are expected to be significantly reduced. Industry observers expect the timeline to reach clinical trials will be shortened.
The government plans to use this cell line supply as an opportunity to drive qualitative growth by shifting the bio-industry structure from a generics-centered model to one focused on therapeutics development. The strategy aims to simultaneously secure competitiveness in both artificial blood and regenerative medicine based on high-quality cellular resources.
"Establishing a national cell bank is core infrastructure that lowers the entry barrier for regenerative medicine research," KDCA Commissioner Lim Seung-gwan said. "We will develop it into a global-level cellular resource platform."